Genta Sinks to Q2 Loss After Sanofi Ends Alliance, Sees Life Left in Genasense as FDA Review Looms

/Home/Biologics Delivery - Protein Synthesis/RNA - Protein Synthesis/RNAi - Protein Synthesis

Genta Sinks to Q2 Loss After Sanofi Ends Alliance, Sees Life Left in Genasense as FDA Review Looms
By Doug Macron
August 10, 2006
RNAi News
Though Genta was hurt after Sanofi-Aventis withdrew from the companies? collaboration to develop Genasense, the drug is still set to go before US and European regulators for various oncology indications.
Paid subscription is required to view article.